ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease
Seeking Alpha / 6 hours ago 1 Views
ZyVersa's IC 100 blocked microglial NLRP1 inflammasome activation and reduced alpha-synuclein accumulation supporting its potential for Parkinson's Disease
Comments